Citations

Clear

55 citation(s) found for "Charles, David".

Does the trait anxiety affect the dental fear?
Doğaner, Yusuf Çetin , Aydoğan, Ümit , YESIL, Hande Ucler , Rohrer, James E. , Williams, Mark Douglas, Agerter, David C., Agerter, David Charles

Mayo Clinic

Brazilian Oral Research | May 5, 2017 | Volume: 31 | Pages: No page available

10.1590/1807-3107bor-2017.vol31.0036 | PMID 28513787 Get It

A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets
Li, Zhipeng , Schulze, Ryan J. , Weller, Shaun G. , Krueger, Eugene W. , Liu, Jun , Stöckli, Jacqueline, James, David E. , McNiven, Mark A. , Schott, Micah B. , Liu, Jun , Stöckli, Jacqueline , James, David E , Zhang, Xiaodong , Casey, Carol A.

Mayo Clinic

Science Advances | December 17, 2016 | Volume: 2 | Issue: 12 | Pages: No page available

10.1126/sciadv.1601470 | PMID 28028537 Get It

A novel protein complex facilitates lipid droplet autophagy.
Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry
Molho, Eric , Stacy, Mark, Gillard, Patrick, Charles, David , Schwartz, Marc , Brin, Mitchell F. , Adler, Charles H. , Jankovic, Joseph J.

Mayo Clinic

Movement Disorders Clinical Practice | December 16, 2015 | Volume: 3 | Issue: 2 | Pages: 130-138

10.1002/mdc3.12238 | PMID 27774495 Get It

Abstract Background Cervical dystonia is thought to result in high disease burden, but limited information exists on its impact on employment and work productivity. We utilized data from the Cervical Dystonia Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (ClinicalTrials.gov identifier: NCT 00836017) to assess the impact of cervical dystonia on employment and work productivity and examine the effect of onabotulinumtoxinA treatments on work productivity. Methods Subjects completed a questionnaire on employment status and work productivity at baseline and final visit. Baseline data were examined by severity of cervical dystonia, predominant subtype, presence of pain, prior exposure to botulinum toxin, and/or utility of a sensory trick. Work productivity results at baseline and final visit were compared in subjects who were toxin‐naïve at baseline and received three onabotulinumtoxinA treatments. Results Of 1,038 subjects, 42.8% were employed full‐ or part‐time, 6.1% unemployed, 32.7% retired, and 11.8% disabled. Of those currently employed, cervical dystonia affected work status of 26.0%, caused 29.8% to miss work in the past month (mean, 5.1 ± 6.4 days), and 57.8% reported decreased productivity. Half of those unemployed were employed when symptoms began, and 38.5% attributed lost employment to cervical dystonia. Pain, increasing severity, and anterocollis/retrocollis had the largest effects on work status/productivity. Preliminary analyses showed that absenteeism and presenteeism were significantly decreased following onabotulinumtoxinA treatments in the subpopulation that was toxin‐naïve at baseline. Conclusions This analysis confirms the substantial negative impact of cervical dystonia on employment, with cervical dystonia‐associated pain being a particularly important driver. OnabotulinumtoxinA treatment appears to improve work productivity.
Evidence for the Role of B Cells and Immunoglobulins in the Pathogenesis of Multiple Sclerosis
Wootla, Bharath , Đenić, Aleksandar , Astapenko, David , Warrington, Arthur E. , Bieber, Allan J., Rodriguez, Moses , Keegan, B. Mark , Winters, Jeffrey L. , Wootla, Bharath , Denic, Aleksandar , Rodriguez, Moses

Mayo Clinic

Neurology Research International | September 22, 2011 | Volume: 2011 | Issue: No issue available | Pages: 1-14

10.1155/2011/780712 | PMID 21961063 Get It

The pathogenesis of multiple sclerosis (MS) remains elusive. Recent reports advocate greater involvement of B cells and immunoglobulins in the initiation and propagation of MS lesions at different stages of their ontogeny. The key role of B cells and immunoglobulins in pathogenesis was initially identified by studies in which patients whose fulminant attacks of demyelination did not respond to steroids experienced remarkable functional improvement following plasma exchange. The positive response to Rituximab in Phase II clinical trials of relapsing-remitting MS confirms the role of B cells. The critical question is how B cells contribute to MS. In this paper, we discuss both the deleterious and the beneficial roles of B cells and immunoglobulins in MS lesions. We provide alternative hypotheses to explain both damaging and protective antibody responses.
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Frye, Robin, Turner, Maria L., Allen, Steven L. , Kirschbaum, Mark, Zain, Jasmine , Prince, H. Miles , Leonard, John P. , Geskin, Larisa J. , Reeder, Craig B. , Joske, David, Figg, William D. , Gardner, Erin R., Steinberg, Seth M. , Stetler‐Stevenson, Maryalice , Lade, Stephen , Fojo, Antonio Tito, Bates, Susan E. , Piekarz, Richard , Wright, John Joseph , Jaffe, Elaine S. , Prince, H Miles , Bates, Susan E

Mayo Clinic

Journal of Clinical Oncology | October 14, 2009 | Volume: 27 | Issue: 32 | Pages: 5410-5417

10.1200/jco.2008.21.6150 | PMID 19826128 Get It

Purpose Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of observed responses in a phase I trial, a phase II trial of romidepsin in patients with T-cell lymphoma was initiated. Patients and Methods The initial cohort was limited to patients with cutaneous T-cell lymphoma (CTCL), or subtypes mycosis fungoides or Sézary syndrome, who had received no more than two prior cytotoxic regimens. There were no limits on other types of therapy. Subsequently, the protocol was expanded to enroll patients who had received more than two prior cytotoxic regimens. Results Twenty-seven patients were enrolled onto the first cohort, and a total of 71 patients are included in this analysis. These patients had undergone a median of four prior treatments, and 62 patients (87%) had advanced-stage disease (stage IIB, n = 15; stage III, n= 6; or stage IV, n = 41). Toxicities included nausea, vomiting, fatigue, and transient thrombocytopenia and granulocytopenia. Pharmacokinetics were evaluated with the first administration of romidepsin. Complete responses were observed in four patients, and partial responses were observed in 20 patients for an overall response rate of 34% (95% CI, 23% to 46%). The median duration of response was 13.7 months. Conclusion The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.